Posted by Michael Wonder on 12 Mar 2025
PHARMAC to fund more cancer medicines (March 2025)
12 March 2025 - PHARMAC is funding six more medicines for cancers and one for antibiotic resistant infections.
The following medicines will be funded from 1 April 2025:
- Nivolumab (Opdivo) and ipilimumab (Yervoy) for clear cell kidney cancer that has spread
- Axitinib (Inlyta) for clear cell kidney cancer that has spread and worsened after trying other medicines
- Sunitinib maleate for kidney cancer that has spread at any point of treatment
- Inotuzumab ozogamicin (Besponsa) for a type of blood cancer called acute lymphoblastic leukaemia that has come back after prior treatment
- Crizotinib (Xalkori) for a type of advanced non-small cell lung cancer with an ROS1 mutation
- Ceftazidime with avibactam (Zavicefta) for antibiotic resistant infections
